Activation of Vitamin D Receptor Pathway Enhances Differentiating Capacity in Acute Myeloid Leukemia with Isocitrate Dehydrogenase Mutations

Simple Summary Around 15% of acute myeloid leukemia (AML) patients harbor mutations in isocitrate dehydrogenases (IDH), which lead to the production of the oncometabolite 2-hydroxyglutarate (2-HG). Inhibitors of mutant IDH enzymes and their 2-HG production have been approved by the FDA to be used in patients. However, 60% of IDH mutant AML patients do not respond to these inhibitors or develop mechanisms of resistance, leading to relapse. Among these mechanisms, some produce a 2-HG rebound. Alternative therapies exploiting the 2-HG-dependent molecular effects could therefore be of clinical interest. In this study, we demonstrate that 2-HG specifically activates vitamin D receptor (VDR) in IDH mutant AML cells leading to increased sensitivity to the combination of vitamin D (or VDR agonist) and all-trans retinoic acid and revealing a new therapeutic approach that can be readily applied to AML patients in this subgroup. Abstract Relapses and resistance to therapeutic agents are major barriers in the treatment of acute myeloid leukemia (AML) patients. These unfavorable outcomes emphasize the need for new strategies targeting drug-resistant cells. As IDH mutations are present in the preleukemic stem cells and systematically conserved at relapse, targeting IDH mutant cells could be essential to achieve a long-term remission in the IDH mutant AML subgroup. Here, using a panel of human AML cell lines and primary AML patient specimens harboring IDH mutations, we showed that the production of an oncometabolite (R)-2-HG by IDH mutant enzymes induces vitamin D receptor-related transcriptional changes, priming these AML cells to differentiate with pharmacological doses of ATRA and/or VD. This activation occurs in a CEBPα-dependent manner. Accordingly, our findings illuminate potent and cooperative effects of IDH mutations and the vitamin D receptor pathway on differentiation in AML, revealing a novel therapeutic approach easily transferable/immediately applicable to this subgroup of AML patients.

[1]  F. Jourdan,et al.  Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia , 2021, The Journal of experimental medicine.

[2]  Marcel H. Schulz,et al.  A hierarchical regulatory network analysis of the vitamin D induced transcriptome reveals novel regulators and complete VDR dependency in monocytes , 2021, Scientific Reports.

[3]  Lei Jiang,et al.  R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis. , 2021, Molecular cell.

[4]  Erika J. Thompson,et al.  Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia , 2020, Nature Communications.

[5]  F. Pasquier,et al.  Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study , 2020, Leukemia & lymphoma.

[6]  E. Marcinkowska,et al.  Investigating the Role of Methylation in Silencing of VDR Gene Expression in Normal Cells during Hematopoiesis and in Their Leukemic Counterparts , 2020, Cells.

[7]  Jingxuan Chen,et al.  Vitamin D and its analogs as anticancer and anti-inflammatory agents. , 2020, European journal of medicinal chemistry.

[8]  M. Konopleva,et al.  Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. , 2020, Cancer discovery.

[9]  H. Dombret,et al.  Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow. , 2020, Cell reports.

[10]  S. Choe,et al.  Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. , 2019, Blood.

[11]  S. Choe,et al.  Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia , 2019, Blood.

[12]  J. Clohessy,et al.  Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy , 2019, Cell Research.

[13]  R. Collins,et al.  Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia , 2019, Leukemia.

[14]  R. Satija,et al.  Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression , 2019, Genome Biology.

[15]  I. Flinn,et al.  Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. , 2019, Blood.

[16]  J. Onuchic,et al.  Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways , 2019, Proceedings of the National Academy of Sciences.

[17]  C. Dinardo,et al.  Advances in patient care through increasingly individualized therapy , 2019, Nature Reviews Clinical Oncology.

[18]  L. Bullinger,et al.  Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care , 2018, Leukemia.

[19]  H. Kantarjian,et al.  Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia , 2018, Haematologica.

[20]  A. Viale,et al.  Isoform switching as a mechanism of acquired resistance to isocitrate dehydrogenase inhibition , 2018, bioRxiv.

[21]  I. Kline,et al.  Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study , 2018, JAMA oncology.

[22]  R. Collins,et al.  Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML , 2018, The New England journal of medicine.

[23]  Bo Wang,et al.  Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations , 2018, Nature.

[24]  Paul Hoffman,et al.  Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.

[25]  James E. Bradner,et al.  R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling , 2018, Cell.

[26]  Geoffrey Brown,et al.  Acute Myeloid Leukaemia: New Targets and Therapies , 2017, International journal of molecular sciences.

[27]  C. Carlberg,et al.  Selective regulation of biological processes by vitamin D based on the spatio-temporal cistrome of its receptor. , 2017, Biochimica et biophysica acta. Gene regulatory mechanisms.

[28]  P. Vyas,et al.  Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. , 2017, Blood.

[29]  Francine E. Garrett-Bakelman,et al.  Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. , 2017, Cancer discovery.

[30]  I. Flinn,et al.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.

[31]  C. Bloomfield,et al.  Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[33]  C. Junot,et al.  Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia , 2016, The Journal of experimental medicine.

[34]  M. Wetzler,et al.  Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia , 2015, American journal of hematology.

[35]  Yangang Wang,et al.  Serum 25-Hydroxyvitamin D Levels and Prognosis in Hematological Malignancies: A Systematic Review and Meta-Analysis , 2015, Cellular Physiology and Biochemistry.

[36]  R. Majeti,et al.  Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia , 2015, Nature Medicine.

[37]  E. Giovannucci,et al.  The role of vitamin D in reducing cancer risk and progression , 2014, Nature Reviews Cancer.

[38]  Benjamin L. Ebert,et al.  (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible , 2013, Science.

[39]  A. Iafrate,et al.  Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. , 2012, Blood.

[40]  D. Margolis,et al.  Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. , 2012, Blood.

[41]  E. Marcinkowska,et al.  Opposite regulation of vitamin D receptor by ATRA in AML cells susceptible and resistant to vitamin D-induced differentiation , 2012, The Journal of Steroid Biochemistry and Molecular Biology.

[42]  S. Berger,et al.  IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.

[43]  X. Thomas,et al.  Serum 25-hydroxyvitamin D levels are associated with prognosis in hematological malignancies , 2011, Hematology.

[44]  E. Marcinkowska,et al.  Differentiation Therapy of Acute Myeloid Leukemia , 2011, Cancers.

[45]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[46]  M. Fackler,et al.  DNA methylation-related vitamin D receptor insensitivity in breast cancer , 2010, Cancer biology & therapy.

[47]  P. Dhawan,et al.  CCAAT Enhancer-binding Protein α Is a Molecular Target of 1,25-Dihydroxyvitamin D3 in MCF-7 Breast Cancer Cells* , 2009, Journal of Biological Chemistry.

[48]  J. Esteve,et al.  Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. , 2009, Blood.

[49]  Bas J. Wouters,et al.  Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling , 2009, Haematologica.

[50]  Xuening Wang,et al.  Regulation of C/EBPβ isoforms by MAPK pathways in HL60 cells induced to differentiate by 1,25-dihydroxyvitamin D3 , 2006 .

[51]  H. Koeffler,et al.  Vitamin D compounds in leukemia , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[52]  C. Trautwein,et al.  Functional Cooperation between CCAAT/Enhancer-Binding Proteins and the Vitamin D Receptor in Regulation of 25-Hydroxyvitamin D3 24-Hydroxylase , 2005, Molecular and Cellular Biology.

[53]  G. P. Studzinski,et al.  Retinoblastoma Protein and CCAAT/Enhancer-Binding Protein β Are Required for 1,25-Dihydroxyvitamin D3-Induced Monocytic Differentiation of HL60 Cells , 2004, Cancer Research.

[54]  C. Carlberg,et al.  Modulation of vitamin D signaling by the pioneer factor CEBPA. , 2019, Biochimica et biophysica acta. Gene regulatory mechanisms.